| Title |
Nivolumab in the treatment of malignant melanoma: review of the literature
|
|---|---|
| Published in |
OncoTargets and therapy, August 2015
|
| DOI | 10.2147/ott.s62102 |
| Pubmed ID | |
| Authors |
Emi Mashima, Akiha Inoue, Yumiko Sakuragi, Takashi Yamaguchi, Natsuko Sasaki, Yoko Hara, Daisuke Omoto, Shun Ohmori, Sanehito Haruyama, Yu Sawada, Manabu Yoshioka, Daisuke Nishio, Motonobu Nakamura |
| Abstract |
Nivolumab was developed as a monoclonal antibody against programmed death receptor-1, an immune checkpoint inhibitor which negatively regulates T-cell proliferation and activation. Intravenous administration of nivolumab was approved for the treatment of unresectable malignant melanoma in 2014 in Japan. When advanced melanoma patients were treated with nivolumab, median overall survival became longer. Overall survival rate was significantly better in nivolumab-treated melanoma patients than dacarbazine-treated melanoma patients. Nivolumab had an acceptable long-term tolerability profile, with 22% of patients experiencing grade 3 or 4 adverse events related to the drug. Therefore, nivolumab can become an alternative therapy for advanced malignant melanoma. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 62 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 2 | 3% |
| Poland | 1 | 2% |
| Unknown | 59 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 13 | 21% |
| Student > Master | 9 | 15% |
| Researcher | 9 | 15% |
| Student > Ph. D. Student | 9 | 15% |
| Student > Doctoral Student | 4 | 6% |
| Other | 8 | 13% |
| Unknown | 10 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 23 | 37% |
| Agricultural and Biological Sciences | 9 | 15% |
| Biochemistry, Genetics and Molecular Biology | 6 | 10% |
| Immunology and Microbiology | 4 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 5% |
| Other | 5 | 8% |
| Unknown | 12 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 August 2015.
All research outputs
#20,816,184
of 25,576,275 outputs
Outputs from OncoTargets and therapy
#1,608
of 3,021 outputs
Outputs of similar age
#202,753
of 276,796 outputs
Outputs of similar age from OncoTargets and therapy
#56
of 97 outputs
Altmetric has tracked 25,576,275 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,021 research outputs from this source. They receive a mean Attention Score of 3.0. This one is in the 30th percentile – i.e., 30% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 276,796 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 97 others from the same source and published within six weeks on either side of this one. This one is in the 34th percentile – i.e., 34% of its contemporaries scored the same or lower than it.